Atlas Trials

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Clinical trial NCT05004350 · COMPLETED

Trial details

NCT number
NCT05004350
Sponsor
Pierre Fabre Medicament
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
BRAF V600EMetastatic Colorectal Cancer
Start date
2021-09-14
Primary completion
2023-12-19
Enrollment
107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.